The size of the Vaccine Adjuvant Market in the Asia Pacific was worth USD 104.3 million in 2020 and estimated to be growing at a CAGR of 11.73% to reach USD 181.61 million by 2025.
Vaccine adjuvants are desirable to expand the adaptive immune reactions to antigens. Adjuvants show their effects through diverse mechanisms. Some adjuvants work as delivery systems that provide stimulation of the immune system. Immunologic adjuvants are added to vaccines for the stimulus of the reaction of the immune system to the target antigen, but directly do not offer immunity. Adjuvants may act in several ways to present an antigen in the immune system. Adjuvants may also serve as the annoyance to involve and intensify the body's immune response.
Factors driving the world vaccine adjuvants market are increasing funding of government in R&D, high occurrence of diseases, the growing emphasis on improved vaccines, and progressive strategic moves assumed by companies such as contracts, acquisitions, and associations.
However, the side effects of adjuvants and the cost of adjuvant growth restrict market growth.
This research report segmented and sub-segmented into the following categories:
Regionally, China, and India, being developing countries with an increase in population, are estimated to grow at the highest CAGR in the forecast period.
Indian vaccine adjuvant market has the largest share in the Asia Pacific market in 2019. The World health organization (WHO) estimated that there are 15 million cases of malaria with 19000-20000 deaths every year in India. In 2020, the collaboration between Novavax and the serum institute of India has introduced next-generation commercial vaccine adjuvant to treat the infectious disease. It helps to boost the Indian vaccine adjuvant market. Recently, the Indian government developing its drug discovery and innovation in vaccine adjuvant with collaboration with the US research center is driving the growth of the Indian vaccine adjuvant market.
In China, Biodegradable nanomaterial and nanotechnology have played a crucial role in the development of vaccine adjuvant due to its application such as better immune effect, less toxic, and accuracy in dose are factors driving the growth of Chinese vaccine adjuvant market. Also, rising coronavirus patients in china and development in healthcare industries like CpG 1018 product offering to boost immune response in China is fuelling the growth of the market. Chine has the most massive burden of Hepatitis-B disease, and nearly 70 million people infected by this disease in 2018 are propelling the growth of the vaccine adjuvants market in China.
The new vaccine and adjuvant center were established in Japan for the development of immune response against disease as well as other diseases such as Alzheimer’s, hypertension, and epilepsy.
Leading companies operating in the APAC Vaccine Adjuvant Market profiled in this report are MPV Technologies, Avanti Polar Lipids, Novavax Inc. Brenntag Biosector, SEPPIC, Agenus, Inc., Invivogen, SPI Pharma, Inc., CSL Limited, and OZ Biosciences.
1. Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 New Developments
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 By Type
5.1.1 Aluminium Salts
5.1.2 Tensoactive Adjuvants
5.1.3 Adjuvant Emulsions
5.1.4 Bacteria derived Adjuvants
5.1.5 Liposome Adjuvants
5.1.6 Carbohydrate Adjuvants
5.2 By Route of Administration
5.2.1 Oral
5.2.2 Intradermal
5.2.3 Subcutaneous
5.2.4 Intranasal
5.2.5 Intramuscular
5.3 By Mechanism of Action
5.3.1 Immuno Stimulants
5.3.2 Carriers
5.3.3 Vehicle Adjuvants
6. Geographical Analysis
6.3 Asia-Pacific
6.1 Introduction
6.2 China
6.3 India
6.4 Japan
6.5 South Korea
6.6 Australia
7. Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 MPV Technologies
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Strategic Evaluation and Operations
8.1.4 Financial analysis
8.1.5 Legal issues
8.1.6 Recent Developments
8.1.7 SWOT analysis
8.1.8 Analyst View
8.2 Avanti Polar Lipids
8.3 Novavax Inc.
8.4 Brenntag Biosector
8.5 SEPPIC
8.6 Agenus, Inc.
8.7 Invivogen
8.8 SPI Pharma Inc.
8.9 CSL Limited
8.10 OZ Biosciences
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10. Expert Opinions
10.1 Market Outlook
10.2 Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
